FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229073014> ?p ?o ?g. }

• W4229073014 abstract "Abstract BackgroundCorticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19). In the RECOVERY trial, the use of dexamethasone reduced 28-day mortality compared to standard care in hospitalized patients with suspected or confirmed COVID-19 requiring supplemental oxygen or invasive mechanical ventilation. No benefit in patients not requiring respiratory support at randomization was observed. However, we believe that the use of corticosteroids in patients with COVID-19 pneumonia might not be subject to a decision based solely on oxygen needs. Evidence has shown that 30% of COVID-19 patients with mild symptoms at presentation will progress to acute respiratory distress syndrome (ARDS), particularly patients in whom laboratory inflammatory biomarkers associated with COVID-19 disease progression are detected. We postulated that dexamethasone treatment in hospitalized patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease might lead to a decrease in the development of ARDS, and thereby reduce death.Methods/designThis is a multicenter, randomized, controlled, parallel, open-label trial testing dexamethasone in 252 adult patients with COVID-19 pneumonia who do not require supplementary oxygen on admission, but are at risk factors for development ARDS. Risk for development ARDS is defined as levels of lactate dehydrogenase >245 U/L, C-reactive protein >100 mg/L, and lymphocyte count of <0.80 × 10 9 /L. Eligible patients will be randomly assigned to receive either dexamethasone or standard of care. Patients in the dexamethasone group will receive an intravenous dose of 6 mg once daily from day 1 to day 3, followed by an oral dose of 6 mg once daily from day 4 to day 7. The primary outcome is a composite of development of moderate ARDS and all-cause mortality during the 30-day period following enrollment.DiscussionIf our hypothesis is correct, the results of this study will provide additional insights about the management and progression of this specific subpopulation of patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease.Trial registrationClinicalTrials.gov NCT04836780. Registered on 8 April 2021 as EARLY-DEX COVID-19." @default.
• W4229073014 created "2022-05-08" @default.
• W4229073014 creator A5009793865 @default.
• W4229073014 creator A5013216682 @default.
• W4229073014 creator A5018164852 @default.
• W4229073014 creator A5027252337 @default.
• W4229073014 creator A5029640098 @default.
• W4229073014 creator A5029781520 @default.
• W4229073014 creator A5030265958 @default.
• W4229073014 creator A5038946064 @default.
• W4229073014 creator A5043709291 @default.
• W4229073014 creator A5044272015 @default.
• W4229073014 creator A5048089302 @default.
• W4229073014 creator A5049493341 @default.
• W4229073014 creator A5057741168 @default.
• W4229073014 creator A5058450806 @default.
• W4229073014 creator A5062815224 @default.
• W4229073014 creator A5063130583 @default.
• W4229073014 creator A5064858160 @default.
• W4229073014 creator A5064889256 @default.
• W4229073014 creator A5071268289 @default.
• W4229073014 creator A5072661045 @default.
• W4229073014 creator A5075358099 @default.
• W4229073014 creator A5076926219 @default.
• W4229073014 creator A5088638220 @default.
• W4229073014 creator A5089136773 @default.
• W4229073014 creator A5089730894 @default.
• W4229073014 date "2022-05-06" @default.
• W4229073014 modified "2023-09-26" @default.
• W4229073014 title "Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial" @default.
• W4229073014 doi "https://doi.org/10.21203/rs.3.rs-1100665/v1" @default.
• W4229073014 hasPublicationYear "2022" @default.
• W4229073014 type Work @default.
• W4229073014 citedByCount "0" @default.
• W4229073014 crossrefType "posted-content" @default.
• W4229073014 hasAuthorship W4229073014A5009793865 @default.
• W4229073014 hasAuthorship W4229073014A5013216682 @default.
• W4229073014 hasAuthorship W4229073014A5018164852 @default.
• W4229073014 hasAuthorship W4229073014A5027252337 @default.
• W4229073014 hasAuthorship W4229073014A5029640098 @default.
• W4229073014 hasAuthorship W4229073014A5029781520 @default.
• W4229073014 hasAuthorship W4229073014A5030265958 @default.
• W4229073014 hasAuthorship W4229073014A5038946064 @default.
• W4229073014 hasAuthorship W4229073014A5043709291 @default.
• W4229073014 hasAuthorship W4229073014A5044272015 @default.
• W4229073014 hasAuthorship W4229073014A5048089302 @default.
• W4229073014 hasAuthorship W4229073014A5049493341 @default.
• W4229073014 hasAuthorship W4229073014A5057741168 @default.
• W4229073014 hasAuthorship W4229073014A5058450806 @default.
• W4229073014 hasAuthorship W4229073014A5062815224 @default.
• W4229073014 hasAuthorship W4229073014A5063130583 @default.
• W4229073014 hasAuthorship W4229073014A5064858160 @default.
• W4229073014 hasAuthorship W4229073014A5064889256 @default.
• W4229073014 hasAuthorship W4229073014A5071268289 @default.
• W4229073014 hasAuthorship W4229073014A5072661045 @default.
• W4229073014 hasAuthorship W4229073014A5075358099 @default.
• W4229073014 hasAuthorship W4229073014A5076926219 @default.
• W4229073014 hasAuthorship W4229073014A5088638220 @default.
• W4229073014 hasAuthorship W4229073014A5089136773 @default.
• W4229073014 hasAuthorship W4229073014A5089730894 @default.
• W4229073014 hasBestOaLocation W42290730141 @default.
• W4229073014 hasConcept C126322002 @default.
• W4229073014 hasConcept C141983124 @default.
• W4229073014 hasConcept C168563851 @default.
• W4229073014 hasConcept C177713679 @default.
• W4229073014 hasConcept C2776348555 @default.
• W4229073014 hasConcept C2776888751 @default.
• W4229073014 hasConcept C2777714996 @default.
• W4229073014 hasConcept C2777914695 @default.
• W4229073014 hasConcept C2780401358 @default.
• W4229073014 hasConcept C42219234 @default.
• W4229073014 hasConcept C71924100 @default.
• W4229073014 hasConceptScore W4229073014C126322002 @default.
• W4229073014 hasConceptScore W4229073014C141983124 @default.
• W4229073014 hasConceptScore W4229073014C168563851 @default.
• W4229073014 hasConceptScore W4229073014C177713679 @default.
• W4229073014 hasConceptScore W4229073014C2776348555 @default.
• W4229073014 hasConceptScore W4229073014C2776888751 @default.
• W4229073014 hasConceptScore W4229073014C2777714996 @default.
• W4229073014 hasConceptScore W4229073014C2777914695 @default.
• W4229073014 hasConceptScore W4229073014C2780401358 @default.
• W4229073014 hasConceptScore W4229073014C42219234 @default.
• W4229073014 hasConceptScore W4229073014C71924100 @default.
• W4229073014 hasLocation W42290730141 @default.
• W4229073014 hasOpenAccess W4229073014 @default.
• W4229073014 hasPrimaryLocation W42290730141 @default.
• W4229073014 hasRelatedWork W1036170284 @default.
• W4229073014 hasRelatedWork W2000389985 @default.
• W4229073014 hasRelatedWork W2114198201 @default.
• W4229073014 hasRelatedWork W2357181119 @default.
• W4229073014 hasRelatedWork W2396308128 @default.
• W4229073014 hasRelatedWork W2404997886 @default.
• W4229073014 hasRelatedWork W2407102458 @default.
• W4229073014 hasRelatedWork W2422272405 @default.
• W4229073014 hasRelatedWork W2422289709 @default.
• W4229073014 hasRelatedWork W3089194506 @default.
• W4229073014 isParatext "false" @default.
• W4229073014 isRetracted "false" @default.
• W4229073014 workType "article" @default.